BACKGROUND: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. OBJECTIVES: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. METHODS:A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. RESULTS: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). CONCLUSIONS:Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).
RCT Entities:
BACKGROUND: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. OBJECTIVES: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. METHODS: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. RESULTS: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). CONCLUSIONS:Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).
Authors: James L Januzzi; Shafiq U Rehman; Asim A Mohammed; Anju Bhardwaj; Linda Barajas; Justine Barajas; Han-Na Kim; Aaron L Baggish; Rory B Weiner; Annabel Chen-Tournoux; Jane E Marshall; Stephanie A Moore; William D Carlson; Gregory D Lewis; Jordan Shin; Dorothy Sullivan; Kimberly Parks; Thomas J Wang; Shawn A Gregory; Shanmugam Uthamalingam; Marc J Semigran Journal: J Am Coll Cardiol Date: 2011-10-25 Impact factor: 24.094
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Hanna K Gaggin; Shweta Motiwala; Anju Bhardwaj; Kimberly A Parks; James L Januzzi Journal: Circ Heart Fail Date: 2013-10-10 Impact factor: 8.790
Authors: G Michael Felker; Kevin J Anstrom; Kirkwood F Adams; Justin A Ezekowitz; Mona Fiuzat; Nancy Houston-Miller; James L Januzzi; Daniel B Mark; Ileana L Piña; Gayle Passmore; David J Whellan; Hongqiu Yang; Lawton S Cooper; Eric S Leifer; Patrice Desvigne-Nickens; Christopher M O'Connor Journal: JAMA Date: 2017-08-22 Impact factor: 56.272
Authors: Nasrien E Ibrahim; Hanna K Gaggin; Alexander Turchin; Harshali K Patel; Yang Song; April Trebnick; Gheorghe Doros; Juan F Maya; Christopher P Cannon; James L Januzzi Journal: Eur Heart J Cardiovasc Pharmacother Date: 2019-01-01
Authors: Hanna K Gaggin; Quynh A Truong; Shafiq U Rehman; Asim A Mohammed; Anju Bhardwaj; Kimberly A Parks; Dorothy A Sullivan; Annabel Chen-Tournoux; Stephanie A Moore; A Mark Richards; Richard W Troughton; John G Lainchbury; Rory B Weiner; Aaron L Baggish; Marc J Semigran; James L Januzzi Journal: Congest Heart Fail Date: 2012-12-28
Authors: G Michael Felker; Tariq Ahmad; Kevin J Anstrom; Kirkwood F Adams; Lawton S Cooper; Justin A Ezekowitz; Mona Fiuzat; Nancy Houston-Miller; James L Januzzi; Eric S Leifer; Daniel B Mark; Patrice Desvigne-Nickens; Gayle Paynter; Ileana L Piña; David J Whellan; Christopher M O'Connor Journal: JACC Heart Fail Date: 2014-09-03 Impact factor: 12.035
Authors: Anju Bhardwaj; Shafiq U Rehman; Asim A Mohammed; Hanna K Gaggin; Linda Barajas; Justine Barajas; Stephanie A Moore; Dorothy Sullivan; James L Januzzi Journal: Am Heart J Date: 2012-11 Impact factor: 4.749
Authors: Mona Fiuzat; Justin Ezekowitz; Wendimagegn Alemayehu; Cynthia M Westerhout; Marco Sbolli; Dario Cani; David J Whellan; Tariq Ahmad; Kirkwood Adams; Ileana L Piña; Chetan B Patel; Kevin J Anstrom; Lawton S Cooper; Daniel Mark; Eric S Leifer; G Michael Felker; James L Januzzi; Christopher M O'Connor Journal: JAMA Cardiol Date: 2020-07-01 Impact factor: 14.676
Authors: Vibhu Parcha; Nirav Patel; Rajat Kalra; Garima Arora; James L Januzzi; G Michael Felker; Thomas J Wang; Pankaj Arora Journal: Circulation Date: 2020-09-08 Impact factor: 29.690
Authors: Tetsu Tanaka; Refik Kavsur; Maximilian Spieker; Christos Iliadis; Clemens Metze; Patrick Horn; Atsushi Sugiura; Malte Kelm; Stephan Baldus; Georg Nickenig; Ralf Westenfeld; Roman Pfister; Marc Ulrich Becher Journal: ESC Heart Fail Date: 2021-09-14